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Patterns of Failure Following Multimodal Treatment for 
Medulloblastoma: Long-Term Follow-up Results at a Single Institution
Purpose
The purpose of this study is to investigate the long-term results and appropriateness of 
radiation therapy (RT) for medulloblastoma (MB) at a single institution.
Materials and Methods
We analyzed the clinical outcomes of 106 patients with MB who received RT between 
January 1992 and October 2009. The median age was 7 years (range, 0 to 50 years), and
the proportion of M0, M1, M2, and M3 stages was 60.4%, 8.5%, 4.7%, and 22.6%, respec-
tively. The median total craniospinal irradiation (CSI) and posterior fossa tumor bed dose in
102 patients (96.2%) treated with CSI was 36 Gy and 54 Gy, respectively.
Results
The median follow-up period in survivors was 132 months (range, 31 to 248 months). A
gradual improvement in survival outcomes was observed, with 5-year overall survival rates
of 61.5% in 1990s increasing to 73.6% in 2000s. A total of 29 recurrences (27.4%) devel-
oped at the following sites: five (17.2%) in the tumor bed; five (17.2%) in the posterior fossa
other than the tumor bed; nine (31%) in the supratentorium; and six (20.7%) in the spinal
subarachnoid space only. The four remaining patients showed multiple site recurrences.
Among 12 supratentorial recurrences, five cases recurred in the subfrontal areas. Although
the frequency of posterior fossa/tumor bed recurrences was significantly high among 
patients treated with subtotal resection, other site (other intracranial/spinal) recurrences
were more common among patients treated with gross tumor removal (p=0.016). There
was no case of spinal subarachnoid space relapse from desmoplastic/extensive nodular
histological subtypes.
Conclusion
Long-term follow-up results and patterns of failure confirmed the importance of optimal RT
dose and field arrangement. More tailored multimodal strategies and proper CSI technique
may be the cornerstones for improving treatment outcomes in MB patients.
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Introduction
Since the first report on the efficacy of craniospinal irradi-
ation (CSI) following surgery in 1969 [1], treatment methods
for medulloblastoma (MB) have evolved as a result of 
improvement in radiotherapeutic and neurosurgical tech-
niques, as well as the development of novel combination
chemotherapeutic agents [2,3]. In addition, recent advances
in the genomic characterization and molecular understand-
ing of this tumor will also lead to better targeting and 
individualized treatment of this cancer [4,5]. 
The traditional strategy for treatment of this tumor has
been maximal curative surgical resection, followed by 
optimal radiation therapy (RT) including CSI and systemic
chemotherapy. However, the detailed characteristics of 
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failure patterns after long-term follow-up have not been well
reported. 
This study was conducted in order to assess our long-term
clinical results of multimodal treatment for MB. In particular,
we focused on the analyses of failure patterns after treatment
and discussed appropriate RT technique based on the study
results.
Materials and Methods
1. Study population
Among the 119 MB patients who received RT between 
January 1992 and October 2009, 106 patients were eligible for
inclusion. Patients with initial extraneural metastasis (n=2),
patients who were referred from other institutions after 
recurrence (n=3), patients who were lost to follow-up so that
the disease status could not be traced (n=6), and patients who
were diagnosed with other histopathology in the pathologic
review (n=2) were excluded from this study; the two latter
patients were histologically confirmed with atypical tera-
toid/rhabdoid tumor and anaplastic ependymoma. All 
eligible patients were histopathologically proven to have MB
and received multimodal treatment with a curative aim. 
Patient characteristics are summarized in Table 1. The 
median age was 7 years (range, 0 to 50 years). Cerebrospinal
fluid (CSF) examination was performed in a majority of 
patients (n=97, 91.5%), and 19.8% (n=21) of the cohort
showed positive CSF cytology. Whole spinal magnetic reso-
nance imaging (MRI) was performed in 102 patients (96.2%),
and spinal seeding metastasis was found in 28.4% (n=29). A
total of 85 cases (80.2%) were available for review of patho-
logical subclassification by an experienced neuropathologist.
Table 1. Patient characteristics of 106 medulloblastoma
patients
Characteristic No. (%) 
Age at diagnosis (yr)
! 3 12 (11.3)
> 3 and ! 10 55 (51.9)
> 10 and ! 30 32 (30.2)
> 30 7 (6.6)
Gender
Male 67 (63.2)
Female 39 (36.8)
Initial imaging modality
Brain MRI/CT 4 (3.8) 
Brain MRI/CT+spinal MRI 102 (96.2)
CSF study
Negative 76 (71.7) 
Positive 21 (19.8)
Not performed 9 (8.5)
M staging
0 64 (60.4)
1 9 (8.5)
2 5 (4.7)
3 24 (22.6)
Unknown 4 (3.8)
Extent of surgery
GTR/NTR 56 (52.8)
STR 50 (47.2)
Treatment year
1992-1999 52 (49.1) 
2000-2009 54 (50.9)
Histological subtype
Classic 57 (53.8)
Desmoplastic/extensive nodular 26 (24.5)
Anaplastic/large cell 2 (1.9)
Unknown 21 (19.8)
Use of combined chemotherapy
Yes 88 (83.0)
No 18 (17.0)
CSI dose (Gy)
No CSI 4 (3.8)
! 30 14 (13.2)
> 30 and ! 36 70 (66.0)
> 36 18 (17.0)
Tumor bed total dose (Gy)
No RT 1 (0.9)
< 50 4 (3.8)
" 50 and < 54 2 (1.9)
" 54 99 (93.4)
Table 1. Continued
Characteristic No. (%) 
Surgery-RT interval (mo)
! 1 57 (53.8)
> 1 and ! 2 30 (28.3)
> 2 and ! 3 7 (6.6)
> 3 12 (11.3)
MRI, magnetic resonance imaging; CT, computed tomog-
raphy; CSF, cerebrospinal fluid; GTR, gross total resection;
NTR, near total resection; STR, subtotal resection; CSI,
craniospinal irradiation; RT, radiation therapy.
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There were 57 classic, 26 desmoplastic/extensive nodular
(DM/EN), and two anaplastic/large cell types. CSF spread
was more common in classic subtype, compared with
DM/EN type (52.6% and 31.6% for M0 and M3, respectively
vs. 73.1% and 3.8% for M0 and M3, respectively; p=0.007). 
2. Surgery
All patients underwent curative surgical resection by 
specialized neurosurgeons. Extent of surgical resection was
assessed according to the operation findings and postopera-
tive MRI, which was taken within 48 hours after operation.
Gross total resection (GTR) was defined as total resection of
primary tumor without remnant lesion in both operation
finding and postsurgical MRI. Near total resection (NTR)
was defined as the state of very small residual disease left in
the operation record, but with no significant remnant lesion
in postsurgical MRI. GTR/NTR was achieved in 30.8% of
cases in the 1990s, increasing to 74.1% in the 2000s (p < 0.001). 
In risk stratification, standard-risk group was defined by
localized disease (M0), favorable resection status (GTR/
NTR), and patients with > 3 years of age. High-risk group
was defined as having at least one of the following charac-
teristics: M+ disease, incomplete resection status (subtotal 
resection, STR), or patients with ! 3 years of age.
3. Radiotherapy
A cobalt 60 teletherapy unit (1990s) or 4-6 MV X-rays was
used for delivery of RT. CSI was routinely prescribed for all
but four patients. Whole brain RT with posterior fossa boost
was performed in two adolescent patients due to poor 
general condition. The two remaining patients ! 2 years old
received CSI after disease progression, which occurred 
during pre-RT chemotherapy. The median total dose and
fraction size of CSI in 102 patients who had received CSI
were 36 Gy (range, 21 to 48.5 Gy) and 1.5 Gy (range, 1.5 to
1.8 Gy), respectively. According to the reduced CSI dose 
protocol (protocol initiated from September 2003), CSI dose
of 36 Gy was reduced to 23.4 Gy in patients with a standard-
risk group, and CSI dose of 39-45 Gy was reduced to 
23.4-30.6 Gy in patients with " M1 stage. 
With the introduction of a computed tomography (CT)
simulator in 2000, we applied CSI in the supine position for
patients in poor condition [6]. Currently, we are routinely
using the supine position for CSI. The median total tumor
bed dose and fractional dose were 54 Gy (range, 21 to 60.6
Gy) and 1.8 Gy (range, 1.8 to 2 Gy), respectively. CSF seeding
lesions in imaging studies were treated with additional boost
RT with a dose range of 5.4 to 10.8 Gy. 
RT methods for posterior fossa and tumor bed boost have
changed with time, and 48 patients (45.3%) were treated
using the 3-dimensional conformal RT (3D CRT) technique.
After 2002, posterior fossa fields were reduced to the primary
tumor bed plus a margin of 1.5-2 cm (usually standard risk
group) or posterior fossa up to 45 Gy, followed by a reduced
field to the primary tumor bed plus a margin of 1.5-2 cm.
Treatment sequences were usually CSI followed by focal
tumor bed boost, but patients with pre-existing bone marrow
suppression or poor general condition were treated with
tumor bed first followed by CSI. The median time interval
between surgery and RT was 4.4 weeks (range, 0.3 to 71.1
weeks). RT was delayed more than 3 months in 12 patients,
but the majority of patients in this group (nine patients) were
! 3 years of age. 
4. Chemotherapy 
Combination chemotherapy was administered to 88 
patients (83%). In early periods, chemotherapy was not 
routinely prescribed in standard risk patients. In total, 11 
patients with M0, three with M1, one with M2, and three
with unknown M stage did not receive chemotherapy. 
In patients > 3 years of age, pre-RT chemotherapy of one
cycle followed by RT and subsequent chemotherapy was the
most preferred treatment sequence. During the RT course,
vincristine was administered weekly in most patients. 
Median seven cycles (range, 1 to 12 cycles) of chemotherapy
was administered after RT. Cisplatin and/or cyclophos-
phamide-based combination chemotherapeutic agents 
(vincristine/cisplatin/ACNU/prednisolone, vincristine/
cisplatin/VP16 and vincristine/cisplatin/CCNU) were most
commonly used. From September 2003, four standard-risk
MB patients were enrolled in the reduced CSI dose protocol
(KSPNO M051). Six high-risk MB patients were enrolled in
high-dose chemotherapy, followed by peripheral blood stem
cell transplantation (PBSCT) and reduced CSI dose protocol
[2]. For patients ! 3 years of age, prolonged chemotherapeu-
tic schedule before RT was used routinely in order to delay
RT administration. 
5. Study end-point and statistical analysis
Statistical analysis was performed using PASW ver. 18.0
(SPSS Inc., Chicago, IL). Overall survival (OS) rates were 
calculated from the date of surgery. Disease recurrence was
defined as relapse from no evidence of disease status after
completion of planned treatment including RT. Recurrence,
secondary malignancy, and death from any cause were
counted as events for calculation of event-free survival (EFS).
Recurrence-free interval (RFI) of recurrent cases was calcu-
lated from the date of surgery to the date of disease recur-
rence.
Results
1. Survival and prognostic factors 
The median follow-up duration was 83 months (range, 3
to 248 months) for the entire population and 132 months
(range, 31 to 248 months) for survivors. A total of 43 deaths
(40.6%) occurred from the following causes: 28 deaths after
recurrence; seven deaths from treatment-related toxicities;
three deaths from second malignancies including one case of
acute lymphoblastic leukemia and two brain tumors; three
deaths from pre-RT disease progression in patients ! 2 years
of age; and two deaths from unknown reasons. Five- and 10-
year OS rates were 67.6% and 57.9%, respectively. Five- and
10-year EFS rates were 59.6% and 55.9%, respectively (Fig. 1).
Results of univariate analyses of EFS and OS are shown in
Table 2. Sex, age, M stage, and extent of surgical resection
did not significantly affect EFS or OS in the entire population. 
In a subgroup of 94 patients > 3 years of age, we found that
the total tumor bed dose < 54 Gy was administered in two
patients and surgery-RT interval was delayed for more than
Cancer Res Treat. 2015;47(4):879-888
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Fig. 1.  Kaplan-Meier curves for major study end-points. Overall survival (OS) and event-free survival (EFS) curves in the
entire group (A), OS and EFS according to the risk stratification (B, p=0.248; C, p=0.380), and OS according to recurrence (D,
p < 0.001).
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3 months in three patients, suggesting that most patients had
received a definitive curable dose of RT to the tumor bed
within the optimal postsurgical interval. 
In a subgroup of 12 patients ! 3 years of age, the estimated
median OS was 41 months (range, 5 to 227 months). In five
patients between 2 and 3 years of age, only one patient with
M3 died of disease. The four remaining patients were still
alive without evidence of relapse at the time of analysis 
(survival duration, 146 to 228 months). Among these five 
patients, four received prolonged pre-RT chemotherapy until
the age of 3 years old before RT. One remaining high-risk 
patient was enrolled in the KSPNO M051 protocol and 
received high-dose chemotherapy followed by PBSCT before
RT. In contrast to the outcomes in patients between 2 and 3
years of age, treatment outcomes were poor in the seven 
patients ! 2 years old, with 5-year OS rates of only 28.6% and
five deaths. Three patients died due to disease progression
during postsurgical chemotherapy despite administration of
RT after progression. In the two remaining patients, the
causes of death were chemotherapy-induced toxicity. Two
patients diagnosed in 2005-2006 and treated with GTR,
chemotherapy, and a curable dose of RT (CSI " 30 Gy and
tumor bed dose " 54 Gy) were still alive without disease at
61 and 70 months after diagnosis, respectively. The ages of
these two patients at the time of diagnosis and RT adminis-
tration were 21 and 36 months, and 20 and 37 months, 
respectively.
2. Initial patterns of failure
A total of 29 recurrences were noted (crude rate, 27.4%).
The results of initial patterns of failure are summarized in
Table 3 and representative recurrent cases are shown in Fig. 2.
Among 12 supratentorial recurrences (with or without other
site metastasis), five recurrent cases occurred in the sub-
frontal areas. All five patients with subfrontal recurrences
initially received 3D CRT using a CT simulator. Among 31
supine-positioned patients, three recurred from supine 
position, and among 71 prone-positioned patients, two 
recurred from prone position. Other locations of supratento-
rial recurrence were the third ventricle, periventricular areas,
basal ganglia, parietal lobe, and fronto-temporal lobe. There
were no cases of recurrence in patients with M1 stage.
Boost field reduction from the posterior fossa to the tumor
bed only did not increase the relapse rate in the posterior
fossa area. Posterior fossa recurrences (including tumor bed
and combined spinal recurrences) occurred in 11 (18.3%) out
of 60 patients who received the entire posterior fossa boost,
and three (6.5%) out of 46 patients who received the tumor
bed boost only (p=0.298). Among three recurrences devel-
oped from the tumor bed boost only, two occurred in the
tumor bed and one in the posterior fossa other than the
tumor bed. 
Primary tumor bed/posterior fossa recurrences were more
common in patients treated with STR (11/50 [22%] in STR
vs. 2/56 [3.6%] in GTR; p=0.016). However, other site (other
intracranial/spinal) recurrences were more common in 
patients treated with GTR (11/56 in GTR vs. 5/50 in STR;
p=0.016). Total resection rate was lower in DM/EN subtypes
and all recurrences occurred in the primary tumor bed/
posterior fossa without spinal relapse (GTR rate: 42.3% in
DM/EN vs. 66.7% in classical subtype; p=0.015).
RT methods were marginally associated with the recur-
rence pattern. Overall recurrences were more common in the
2D era (20/58 in 2D vs. 9/48 in 3D; p=0.08). Among 20 
recurrences treated with 2D RT, 11 recurrences developed in
the posterior fossa and five in the spinal area. Among nine
recurrences treated with 3D RT, two recurrences developed
in the posterior fossa and two in the spinal area. 
Among seven patients with spinal relapses, four patients
with M0 received 0, 30, 36, and 36 Gy of CSI, and three 
patients with M3 received 36, 39, and 39 Gy of CSI. 
3. Disease recurrences, salvage treatment and occurrence of
second malignancies
The median RFI after initial surgery was 22 months (range,
3 to 84 months) and the median postrecurrence survival was
11 months (range, 0 to 192 months). Recurrent sites did not
significantly affect OS or postrecurrence survival. 
Salvage treatment modalities were selected according to
the patients’ performance status, disease extent, and the
physicians’ preferences. Reirradiation with a dose range of
19.5 to 41.4 Gy was administered in 12 patients with or with-
out other treatments, and gamma-knife radiosurgery was
performed in one patient. The detailed characteristics of 12
reirradiation cases are shown in Table 4. Salvage surgery was
preferentially performed in the posterior fossa or other soli-
tary intracranial recurrences. Spinal seeding metastasis was
Table 3. Initial patterns of failure
Site No. (%) 
Posterior fossa+intracranial (n=22)
Tumor bed 5 (17.2)
Posterior fossa other than tumor bed 5 (17.2)
Supratentorium 9 (31.0)
Tumor bed+supratentorium 1 (3.4)
Posterior fossa+supratentorium 2 (6.9)
Combined spinal (n=7)
Spine alone 6 (20.7)
Posterior fossa+spine 1 (3.4)
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mainly managed by chemotherapy and/or focal reirradia-
tion. 
Long-lasting survival after successful salvage could be
achieved in only five patients. In these five patients, three 
patients were managed with reirradiation with/without
chemotherapy, one with combination chemotherapy alone,
and the remaining one with salvage surgery, high-dose
chemotherapy, and autologous stem cell transplantation.
Four patients were still alive without evidence of disease
after 192, 143, 41, and 24 months postrecurrence. The remain-
ing patient died after 70 months postrecurrence due to late
second relapse. One patient with initial M0 stage experienced
recurrence at S2-4 levels of subarachnoid space with sacral
bony extension (Fig. 2I). We found that the sacral CSI field
was insufficient, and salvage partial laminectomy,
chemotherapy, and reirradiation of 36 Gy to L5-sacrum were
performed. The patient continued to live without evidence
of disease for 41 months after recurrence. 
Pathologically confirmed second brain tumors developed
in three patients with the following characteristics: atypical
meningioma at the anterior interhemispheric fissure 201
months after RT, low-grade astrocytoma at the left cerebel-
lum 124 months after RT, and anaplastic astrocytoma at the
pons 93 months after RT. The patient with meningioma was
alive at the time of analysis and the two remaining patients
died from the second tumors.
Discussion
Because our patients had received fairly consistent multi-
modal treatment, we could eliminate the impact of RT doses
and volume on outcomes and could assess the appropriate-
ness of the CSI technique. 
Analyses of the recurrence pattern showed that there is
room for improvement in outcomes by improving surgery
and RT techniques. The recurrence rate of primary tumor bed
(20.6%) was relatively low, reflecting the appropriateness of
surgery and RT administration to the tumor bed. However,
the frequency of primary tumor bed/posterior fossa recur-
rence was still higher in cohorts treated by STR. Reduced
boost volume confined to the tumor bed rather than the 
entire posterior fossa did not increase posterior fossa relapse.
We found a high frequency (50% of supratentorial relapses)
of subfrontal recurrence and a sacral relapse after a tight
sacral CSI field. Subfrontal areas near cribriform plates are
potentially high-risk regions of underdose, requiring special
concerns in the RT field design [7,8]. Excessive eye-sparing
RT technique or unstable prone CSI position might increase
the risk of relapse in these areas. In our study, all five 
subfrontal recurrences developed in the 3D era and excessive
eye-block might have caused the recurrences. Another 
hypothesis suggested by Sun et al. [7] is that lying in the
prone position during the operation could facilitate the 
migration of tumor cells to the cribriform plate due to the
gravitational effect, which might cause subsequent tumor 
Fig. 2.  Illustrations showing representative recurrent cases. Primary tumor bed recurrence (A, B), posterior fossa recurrence
outside tumor bed (C, D), supratentorial (subfrontal) recurrence (E, F), supratentorial (subfrontal and suprasellar) recurrence
(G, H), and sacral recurrence (I) are shown. 
A B C D
E F G H I
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recurrence. Given the low successful salvage rate of recur-
rence and surgically restorable features of cataracts, proper
coverage of the cribriform plate is warranted. In the modern
era, with the introduction of CT simulation to define accurate
target volumes and more stable supine patient position to
maintain consistent set-up, we expect that recurrence rates
will be reduced.
With changes in time, we observed a gradual improve-
ment in survival outcomes in terms of 5-year OS rates of
61.5% in 1990 to 73.6% in 2000, which might be attributed to
several factors related to the development in surgical, radio-
therapeutic, and chemotherapeutic approaches. The treat-
ment outcome in 2000 was comparable with that of a recent
report [9]. Recently, reduced-dose CSI with chemotherapy
and refined tumor bed boost for sparing critical organs with
3D CRT or intensity-modulated radiation therapy (IMRT)
techniques have resulted in reduced toxicity without a detri-
mental effect on local control [3]. 
The surgical extent, age, M stage, or RT doses that were
considered important for survival outcomes in the prior
studies were not statistically significant prognostic factors in
our study, which is suspected due to the small sample size
or tailored treatment. Patients with M1-M3 received higher
radiation doses than patients with M0. GTR/NTR resulted
in high posterior fossa control, but did not affect survival due
to the high rate of distant relapses. More curable control of a
primary site might change the patterns of disease relapse and
increase distant recurrences [10]. Paulino et al. [3] reported
that distant spinal subarachnoid space recurrences were the
predominant patterns of failure in the high-dose IMRT era.
Young age, although not statistically significant, affected the
prognosis. In patients ! 2 years old, the main contributing
factors for deteriorated OS in early periods were poor toler-
ance to chemotherapy and delayed or reduced doses of RT.
Radical surgery and curable doses of RT delivery could not
usually be given and disease progression during pre-RT
chemotherapy or treatment-related toxicity were the main
reasons for deaths in the 1990s. However, better outcomes
could be achieved after 2000. Our study also showed that the
prognosis of patients between 2 and 3 years of age could be
comparable to that of those > 3 years old, if managed prop-
erly. 
Based on the results of several studies, a reduced CSI dose
of 23.4 Gy and chemotherapy is currently the preferred treat-
ment for standard-risk MB [11,12]. Clinical trials with 
reduced-dose CSI and intensified chemotherapy are 
currently ongoing for high-risk MB patients [2]. In our study,
in high-risk MB patients among 10 (four standard-risk and
six high-risk) patients enrolled in the reduced-dose CSI 
protocol, there was only one case of disease recurrence and
death. This finding is promising, but longer follow-up study
is required. 
The prognostic significance of histological subtype has
been controversial [13,14]. DM/EN subtypes showed low
CSF seeding rate; however, complete resection rate was also
low, which resulted in a high rate of primary site recurrences.
A previous study [15] pointed out that complete resection of
DM histology could be challenging because of the lateralized
location of the tumor, but that the differences in prognosis
between subtypes could be eliminated with improvement of
surgical techniques in the modern era. Our study also found
no statistical difference between the subtypes in terms of OS. 
OS after disease recurrence was significantly deteriorated
and successful salvage was achieved in only five patients 
despite the various efforts of salvage treatments. Among 12
reirradiation cases, there were three successful salvage and
long-term survivors. Bakst et al. [16] reported successful and
promising treatment outcomes after reirradiation with 
median postrecurrence survival of 45 months. They found
that reirradiation was most beneficial to patients with no 
evidence of disease after surgical re-resection and suggested
trimodality therapy as a promising option in recurrent MB.
Conclusion
In conclusion, in our long-term institutional analysis of MB
patients, integration of multimodal treatment including 
maximal surgical resection and proper CSI resulted in a
gradual increase in survival. Our patterns of failure analyses
demonstrated that there is room for improvement in 
outcomes with more sophisticated and optimal RT tech-
niques (complete coverage of craniospinal subarachnoid
space, tailored RT dose according to M stage and reduced
boost volume to the tumor bed only rather than the entire
posterior fossa). The results in our series are encouraging and
we hope to cure this devastating pediatric tumor in the near
future with improved understanding of the disease and more
advanced technological approaches.
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